Pepinemab is under clinical development by Vaccinex and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pepinemab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pepinemab (VX-15) is under development for the treatment of multiple sclerosis (MS), metastatic adenocarcinoma of the pancreas, pancreatic ductal adenocarcinoma, metastatic melanoma, recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), non-small cell lung cancer, Alzheimer's disease, osteosarcoma, squamous cell carcinoma of the head and neck, oropharyngeal cancer, oral cavity cancer, laryngeal cancer, rett syndrome, relapsed/refractory solid tumors such as metastatic colorectal, HER2-positive (HER2+) metastatic breast cancer, papillary thyroid cancer, pancreatic ductal adenocarcinoma and pediatric patients with solid tumors. It is administered intravenously. The drug candidate is a monoclonal antibody targeting semaphorin 4D (SEMA4D). The drug candidate is developed based on proprietary ActivMab technology, which involves a vaccinia virus-based vector to express antibodies in mammalian cells. It was also under development for the treatment of melanoma.
It was under development for the treatment of Huntington's disease.
Vaccinex is a clinical-stage biotechnology company. It discovers and develops targeted biotherapeutics to treat neurodegenerative diseases, cancer and autoimmune disorders. The company’s lead platform technologies include antibody platform and ActivMAb, SEMA4D and antibody discovery platform. Vaccinex through its antibody platform develops its lead product candidate VX15, for the treatment of various indications such as neurodegenerative diseases, neuroinflammatory and cancer. The company also develops VX5 that is in preclinical development for the treatment of autoimmune disorders. It has partnership with biotechnology and biopharmaceutical companies to enhance its product candidates. Vaccinex is headquartered in Rochester, New York, the US.
For a complete picture of Pepinemab’s drug-specific PTSR and LoA scores, buy the report here.